Replies to post #146070 on Anavex Life Sciences Corp (AVXL)

[Investor2014]

I look at screw up done by AVXL CEO and not other companies.

I think it is useful with comparisons for perspective on what screw-ups might look like and indeed to in due course conclude whether the screw-up assessment was correct or not.

In the case of Anavex the approach is entirely different from any other past or current trials in AD. The overall time taken to conclude a P2 and (presumably) soon to initiate a P2/3 trial, is in fact short compared for example to vTv (18 years so far) and the many BP attempts and cost, not to mentioned the large number of disappointed patients and their families.

As for vTv, it seems to me an example of potentially serial screw-ups, and/or Wall St. games, with a drug previously laid off by Pfizer, Inc., adopted by TransTech Pharma, Inc., now vTv Therapeutics, inc. After 18 years, will vTv Therapeutics’ Alzheimer’s drug sink or swim?

The vTv drug, now named Azeliragon is a small-molecule inhibitor of receptor for advanced glycation end products (RAGE) and said to be an upstream approach to Amyloid and Tau. The drug has previously failed and has been shown by vTv to be toxic in concentrations between 5mg - 20mg. The hope is that 5mg is effective.

Despite heavy buying by Ron Perelman, an insider and top shareholder, as well as institutional ownership including BlackRock, the share price has recently plummeted from around $7.80 in Feb 2018 to $4.07 Friday.

Either drug may not ultimately work, on the other hand time may show that Missling is no screw-up. Glad Anavex is not in the grib of Wall St. and the IPO games.